Therapeutic effect of CT-P59 against SARS-CoV-2 South

Citation Report

#	Article	IF	Citations
1	SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. Viruses, 2021, 13, 1211.	3.3	35
2	Tackling COVID-19 with neutralizing monoclonal antibodies. Cell, 2021, 184, 3086-3108.	28.9	309
4	COVID-19: Failure of the DisCoVeRy Clinical Trial, and Nowâ€"New Hopes?. Pharmaceuticals, 2021, 14, 664.	3.8	3
6	Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection. Clinical Therapeutics, 2021, 43, 1706-1727.	2.5	39
7	Modeling Within-Host Dynamics of SARS-CoV-2 Infection: A Case Study in Ferrets. Viruses, 2021, 13, 1635.	3.3	24
8	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. The Cochrane Library, 2021, 2021, CD013825.	2.8	114
10	The inÂvitro and inÂvivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2. Biochemical and Biophysical Research Communications, 2021, 578, 91-96.	2.1	39
11	Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. Cell Discovery, 2021, 7, 96.	6.7	21
12	Regdanvimab: First Approval. Drugs, 2021, 81, 2133-2137.	10.9	38
13	In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein. Frontiers in Immunology, 2021, 12, 782506.	4.8	24
14	Antibodies to watch in 2022. MAbs, 2022, 14, 2014296.	5.2	239
15	Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity scoreâ€"matched retrospective cohort study. International Immunopharmacology, 2022, 106, 108570.	3.8	13
16	SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations. Infection and Drug Resistance, 2022, Volume 15, 373-385.	2.7	24
17	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 0, , .	27.8	101
18	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 2022, 602, 664-670.	27.8	917
21	Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study. Journal of Korean Medical Science, 2022, 37, e102.	2.5	8
22	Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opinion on Investigational Drugs, 2022, 31, 41-58.	4.1	26
23	Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation. Frontiers in Medical Technology, 2022, 4, 867982.	2.5	11

#	ARTICLE	IF	CITATIONS
24	Antigen–Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD. Frontiers in Molecular Biosciences, 2022, 9, 797132.	3.5	3
26	Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir. Drug Design, Development and Therapy, 2022, Volume 16, 827-841.	4.3	12
27	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs, 2022, 36, 231-323.	4.6	24
28	Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study. Current Therapeutic Research, 2022, 96, 100675.	1.2	5
29	Animal models for studying coronavirus infections and developing antiviral agents and vaccines. Antiviral Research, 2022, 203, 105345.	4.1	7
30	Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit. Terapevticheskii Arkhiv, 2022, 94, 675-682.	0.8	1
31	Antibodies to combat viral infections: development strategies and progress. Nature Reviews Drug Discovery, 2022, 21, 676-696.	46.4	68
32	Monoclonal antibody therapies against SARS-CoV-2. Lancet Infectious Diseases, The, 2022, 22, e311-e326.	9.1	114
33	A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019. Open Forum Infectious Diseases, 2022, 9, .	0.9	15
34	Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Emerging Microbes and Infections, 2022, 11, 2315-2325.	6.5	3
35	Two Years into the COVID-19 Pandemic: Lessons Learned. ACS Infectious Diseases, 2022, 8, 1758-1814.	3.8	47
36	Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance. Infection and Chemotherapy, 0, 54, .	2.3	4
37	Antibody-mediated immunity to SARS-CoV-2 spike. Advances in Immunology, 2022, , 1-69.	2.2	12
38	Influenza Infection in Ferrets with SARS-CoV-2 Infection History. Microbiology Spectrum, 0, , .	3.0	0
39	Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case Series. Pediatric Infectious Disease Journal, 2023, 42, 125-129.	2.0	4
40	Ferrets: A powerful model of SARS-CoV-2. Zoological Research, 2023, 44, 323-330.	2.1	1
41	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon, 2023, 9, e13952.	3.2	28
42	Rational strategies for enhancing mAb binding to SARS-CoV-2 variants through CDR diversification and antibody-escape prediction. Frontiers in Immunology, 0, 14, .	4.8	1

#	ARTICLE	IF	CITATIONS
43	SABRes: in silico detection of drug resistance conferring mutations in subpopulations of SARS-CoV-2 genomes. BMC Infectious Diseases, 2023, 23, .	2.9	2
44	Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation. Chemical Society Reviews, 2023, 52, 6497-6553.	38.1	1
45	Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea. Infectious Diseases and Therapy, 2023, 12, 2417-2435.	4.0	0
46	Engineered Therapeutic Antibody Against SARS-CoV-2. Current Clinical Microbiology Reports, 2023, 10, 222-235.	3.4	0